Latest Nintedanib Stories

- Data accepted as late-breaking, oral presentation at ASCO 2013 RIDGEFIELD, Conn., June 3, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from the Phase III LUME-Lung 1 study showing that the addition of the investigational oncology compound nintedanib* to docetaxel improved progression-free survival (PFS) - the primary endpoint - as a second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) compared...

New trial results presented at American Society of Clinical Oncology (ASCO) 2013 represent first advance in almost a decade in overall survival for patients where initial chemotherapy has failed BURLINGTON, ON, June 3, 2013 /CNW/ - New research on Canada's number one cancer killer(1) is further proof that patients need personalized treatments targeted to their specific type of lung cancer for better outcomes.  Boehringer Ingelheim (Canada) Ltd. today announced highly anticipated...

Data Presented at American Society of Clinical Oncology (ASCO) on two Boehringer Ingelheim Phase III Oncology Compounds, Afatinib* and Nintedanib*, Show Progression Free Survival in Patients with Advanced Non-Small Cell Lung Cancer BURLINGTON, ON, May 16, 2013 /CNW/ - New research taking place right here on Canadian soil is shedding light on the nation's number one cancer killer,(i) lung cancer.  Boehringer Ingelheim (Canada) Ltd. today announced data from Phase III clinical...

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds - afatinib* and nintedanib* - in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in...

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds - afatinib*, nintedanib* and volasertib*. Results - to be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013 - are from Boehringer Ingelheim's robust...

New Data Describes the Efficacy of NovoTTF(TM) Therapy in Combination with Chemotherapy in Preclinical Solid Tumor Models WASHINGTON, April 10, 2013 /PRNewswire/ -- Novocure announced today that new data from preclinical testing of NovoTTF Therapy in non-small cell lung carcinoma (NSCLC), ovarian and pancreatic cancer has been presented at the 2013 AACR Annual Meeting. The new data builds on existing published research describing the potential efficacy of NovoTTF Therapy in a wide...

RIDGEFIELD, Conn., Sept. 26, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose. There are no approved treatments in the U.S. for IPF, a progressive and severely debilitating lung disease with a high...

RIDGEFIELD, Conn., Sept. 20, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that data from 13 abstracts assessing the efficacy and safety of two of its investigational oncology compounds - afatinib and nintedanib - were selected for presentation at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria, September 28 - October 2, 2012. These data represent Boehringer Ingelheim's commitment to further develop its oncology pipeline with the...

ROCKVILLE, Md., Sept. 6, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today the publication of an article by Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute in Boston, entitled "ENMD-2076, an Oral Inhibitor of Angiogenic and Proliferation Kinases, Has Activity in Recurrent, Platinum Resistant Ovarian Cancer," in the European Journal of Cancer. (Logo:...